Table 1 Patients characteristics and survival
N (%) | Median OS | Median PFS | ||||
|---|---|---|---|---|---|---|
months | logrank | months | logrank | |||
Age | 47 (15–84) | |||||
<=60 | 145 (80) | 16.9 | 0.05 | 3.3 | 0,13 | |
>60 | 36 (20) | 11.7 | 3.0 | |||
Male | 83 (46) | 14,7 | 0.36 | 3.8 | 0,78 | |
Female | 98 (54) | 16,6 | 3.1 | |||
Site | ||||||
Inf limb | 59 (33) | 17.1 | 0.15 | 4.8 | 0.03 | |
Sup Limb | 12 (7) | 16.6 | 2.3 | |||
Retroperitoneum | 33 (18) | 19.6 | 9.1 | |||
Uterus | 24 (13) | 13.9 | 3.0 | |||
Other trunk | 45 (25) | 9.3 | 2.7 | |||
Head/Neck | 8 (4) | 17.0 | 4.0 | |||
Histotypes | ||||||
LMS | 55 (30) | 17,4 | 0.005 | 3.4 | 0.005 | |
Myxoid LPS | 28 (16) | 33.4 | 10,5 | |||
LPS (other) | 21 (11) | 20.0 | 3.2 | |||
NOS/undiff. | 22 (12) | 14,0 | 2.2 | |||
Synovial | 16 (9) | 9.2 | 4.0 | |||
Others/Misc | 39 (22) | 6.7 | 2.1 | |||
Myxoid LPS | ||||||
Yes | 28 (15) | 33.4 | 0.01 | 10,5 | 0.000 | |
No | 153 (85) | 13.9 | 2.8 | |||
Translocation sarcomas | ||||||
Yes | 54 (30) | 15.3 | 0.17 | 5.3 | 0,02 | |
No | 119 (66) | 14.7 | 2.8 | |||
Grade | ||||||
1 | 17 (9) | 16.9 | 0.43 | 9.7 | 0,17 | |
2 | 51 (28) | 18.6 | 4.4 | |||
3 | 80 (44) | 16.0 | 3.6 | |||
UNK | 33 (19) | 10.7 | 2.8 | |||
Treatment line for ET-743 (median: 3, range 1–4) | ||||||
1* | 10 (6) | 33.4 | 0.03 | 4.5 | 0.04 | |
2 | 67 (37) | 18.2 | 5.3 | |||
3 | 60 (33) | 14.3 | 3.2 | |||
4 | 42 (23) | 10.2 | 2.8 | |||
* doxorubicin and ifosfamide in the adjuvant setting | ||||||
Hospitalisation for toxicity (reported in N = 152) | ||||||
Yes | 30 (17) | 6.7 | 0.03 | 2.5 | 0.39 | |
No | 122 (65) | 18.2 | 4.5 | |||
Lung metastases | ||||||
Yes | 128 (71) | 14.7 | 0.93 | 3.0 | 0.054 | |
No | 47 (25) | 16.9 | 6.7 | |||
Liver metastases | ||||||
Yes | 45 (25) | 16.8 | 0.51 | 3.0 | 0.83 | |
No | 125 (70) | 13.5 | 3.6 | |||